Skip to main content
Top
Published in: Journal of Gastroenterology 2/2021

01-02-2021 | Hepatitis B | Original Article—Liver, Pancreas, and Biliary Tract

The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan

Authors: Hirayuki Enomoto, Yoshiyuki Ueno, Yoichi Hiasa, Hiroki Nishikawa, Shuhei Hige, Yasuhiro Takikawa, Makiko Taniai, Toru Ishikawa, Kohichiroh Yasui, Akinobu Takaki, Koichi Takaguchi, Akio Ido, Masayuki Kurosaki, Tatsuya Kanto, Shuhei Nishiguchi, Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH

Published in: Journal of Gastroenterology | Issue 2/2021

Login to get access

Abstract

Background

We recently reported the real-world changes in the etiologies of liver cirrhosis (LC) based on nationwide survey data and assessed the etiologies of LC with hepatocellular carcinoma (HCC).

Methods

Fifty-five participants from 68 institutions provided data on 23,637 patients with HCC-complicated LC. The changing trends in etiologies were assessed. We further analyzed the data from 29 hospitals that provided the annual number of newly identified HCC-complicated LC patients from 2008 to 2016 (N = 9362) without any missing years and assessed the transition in the real number of newly identified HCC-complicated LC cases.

Results

In the overall cohort, hepatitis C virus (HCV) infection (60.3%) and hepatitis B virus (HBV) infection (12.9%) were the leading and third-most common causes of HCC-complicated LC in Japan, respectively. HCV infection was found to be the leading cause throughout Japan. The rate of viral hepatitis-related HCC decreased from 85.3 to 64.4%. Among non-viral etiologies, notable increases were observed in nonalcoholic steatohepatitis (NASH)-related HCC (from 1.5 to 7.2%) and alcoholic liver disease (ALD)-related HCC (from 8.5 to 18.6%). Regarding the real number of newly diagnosed patients, the number of patients with viral hepatitis-related HCC decreased, while the number of patients with non-viral HCC, particularly NASH-related HCC, increased.

Conclusions

Viral hepatitis has remained the main cause of HCC in Japan. However, the decrease in viral hepatitis-related HCC, particularly HCV-related HCC highly contributed to the etiological changes. In addition, the increased incidence of non-viral HCC, particularly NASH-related HCC, was involved in the changing etiologies of HCC-complicated LC in Japan.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sarin SK, Kumar M, Eslam M, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5:167–228.CrossRef Sarin SK, Kumar M, Eslam M, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5:167–228.CrossRef
2.
go back to reference Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604.CrossRef Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604.CrossRef
5.
go back to reference Oza N, Isoda H, Ono T, et al. Current activities and future directions of comprehensive hepatitis control measures in Japan: the supportive role of the Hepatitis Information Center in building a solid foundation. Hepatol Res. 2017;47:487–96.CrossRef Oza N, Isoda H, Ono T, et al. Current activities and future directions of comprehensive hepatitis control measures in Japan: the supportive role of the Hepatitis Information Center in building a solid foundation. Hepatol Res. 2017;47:487–96.CrossRef
6.
go back to reference Tanaka J, Akita T, Ko K, Miura Y, et al. Countermeasures against viral hepatitis B and C in Japan: an epidemiological point of view. Hepatol Res. 2019;49:990–1002.CrossRef Tanaka J, Akita T, Ko K, Miura Y, et al. Countermeasures against viral hepatitis B and C in Japan: an epidemiological point of view. Hepatol Res. 2019;49:990–1002.CrossRef
7.
go back to reference Spearman CW, Dusheiko GM, Hellard M, et al. Hepatitis C. Lancet. 2019;394:1451–66.CrossRef Spearman CW, Dusheiko GM, Hellard M, et al. Hepatitis C. Lancet. 2019;394:1451–66.CrossRef
8.
go back to reference Tang LSY, Covert E, Wilson E, et al. Chronic hepatitis B Infection: a review. JAMA. 2018;319:1802–13.CrossRef Tang LSY, Covert E, Wilson E, et al. Chronic hepatitis B Infection: a review. JAMA. 2018;319:1802–13.CrossRef
9.
go back to reference Enomoto H, Ueno Y, Hiasa Y, et al. Transition in the etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol. 2020;55:353–62.CrossRef Enomoto H, Ueno Y, Hiasa Y, et al. Transition in the etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol. 2020;55:353–62.CrossRef
10.
go back to reference Doyle A, Sherman M. Primary malignant neoplasms of the liver. In: Dooley JS, Lok ASF, Garcia-Tsao G, Pinzani M, editors. Sherlock's diseases of the liver and biliary system. 13th ed. New Jersey: Wiley-Blackwell; 2018. p. 705–29.CrossRef Doyle A, Sherman M. Primary malignant neoplasms of the liver. In: Dooley JS, Lok ASF, Garcia-Tsao G, Pinzani M, editors. Sherlock's diseases of the liver and biliary system. 13th ed. New Jersey: Wiley-Blackwell; 2018. p. 705–29.CrossRef
11.
go back to reference The Japan Society of Hepatology. Clinical guidelines for management of chronic hepatitis and cirrhosis 2016. Tokyo: Bun-kodo; 2016a. The Japan Society of Hepatology. Clinical guidelines for management of chronic hepatitis and cirrhosis 2016. Tokyo: Bun-kodo; 2016a.
12.
go back to reference The Japan Society of Hepatology. Textbook of hepatology. 2nd ed. Tokyo: Nankodo; 2016b. The Japan Society of Hepatology. Textbook of hepatology. 2nd ed. Tokyo: Nankodo; 2016b.
13.
go back to reference Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol Res. 2020;50:892–923. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol Res. 2020;50:892–923.
14.
go back to reference Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020;50:791–816. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020;50:791–816.
15.
go back to reference Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87–95.CrossRef Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87–95.CrossRef
16.
go back to reference Huang CF, Iio E, Jun DW, et al. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int. 2019;13:587–98.CrossRef Huang CF, Iio E, Jun DW, et al. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int. 2019;13:587–98.CrossRef
17.
go back to reference Toyoda H, Atsukawa M, Watanabe T, et al. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2020;35:855–61.CrossRef Toyoda H, Atsukawa M, Watanabe T, et al. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2020;35:855–61.CrossRef
18.
go back to reference Mashiba T, Joko K, Kurosaki M, et al. Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): a nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. Hepatol Res. 2019;49:1114–20.CrossRef Mashiba T, Joko K, Kurosaki M, et al. Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): a nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. Hepatol Res. 2019;49:1114–20.CrossRef
19.
go back to reference Michitaka K, Nishiguchi S, Aoyagi Y, et al. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol. 2010;45:86–94.CrossRef Michitaka K, Nishiguchi S, Aoyagi Y, et al. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol. 2010;45:86–94.CrossRef
20.
go back to reference Tokushige K, Hashimoto E, Horie Y, et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011;46:1230–7.CrossRef Tokushige K, Hashimoto E, Horie Y, et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011;46:1230–7.CrossRef
21.
go back to reference Kudo M, Izumi N, Kubo S, et al. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2020;50:15–46.CrossRef Kudo M, Izumi N, Kubo S, et al. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2020;50:15–46.CrossRef
22.
go back to reference Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019;54:367–76.CrossRef Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019;54:367–76.CrossRef
23.
go back to reference Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res. 2015;45:59–74.CrossRef Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res. 2015;45:59–74.CrossRef
24.
go back to reference Nagaoki Y, Hyogo H, Aikata H, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2012;42:368–75.CrossRef Nagaoki Y, Hyogo H, Aikata H, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2012;42:368–75.CrossRef
25.
go back to reference Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17:748-755.e3 Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17:748-755.e3
26.
go back to reference Sagnelli E, Macera M, Russo A, et al. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7–17.CrossRef Sagnelli E, Macera M, Russo A, et al. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7–17.CrossRef
27.
go back to reference Singal AK, Satapathy SK, Reau N, et al. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liver Dis. 2020;52:98–101.CrossRef Singal AK, Satapathy SK, Reau N, et al. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liver Dis. 2020;52:98–101.CrossRef
28.
go back to reference Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(477–491):e1. Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(477–491):e1.
29.
go back to reference Mizuno K, Toyoda H, Yasuda S, et al. The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. J Gastroenterol. 2019;54:829–36.CrossRef Mizuno K, Toyoda H, Yasuda S, et al. The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. J Gastroenterol. 2019;54:829–36.CrossRef
30.
go back to reference Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in foreseeable future. Oncology. 2002;62(Suppl1):8–17.CrossRef Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in foreseeable future. Oncology. 2002;62(Suppl1):8–17.CrossRef
Metadata
Title
The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan
Authors
Hirayuki Enomoto
Yoshiyuki Ueno
Yoichi Hiasa
Hiroki Nishikawa
Shuhei Hige
Yasuhiro Takikawa
Makiko Taniai
Toru Ishikawa
Kohichiroh Yasui
Akinobu Takaki
Koichi Takaguchi
Akio Ido
Masayuki Kurosaki
Tatsuya Kanto
Shuhei Nishiguchi
Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH
Publication date
01-02-2021
Publisher
Springer Singapore
Published in
Journal of Gastroenterology / Issue 2/2021
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-020-01748-x

Other articles of this Issue 2/2021

Journal of Gastroenterology 2/2021 Go to the issue